A Clinical Study to Evaluate the Stain Reduction Efficacy of a Non-Fluoride Tooth Whitening Dentifrice Containing Nano-Hydroxyapatite (nHAP) and a High Cleaning Silica Abrasive System Compared to a Commercial Fluoride Non-Whitening Dentifrice as a Negative Control
1 other identifier
interventional
120
1 country
1
Brief Summary
To determine whether brushing with a non-fluoride tooth whitening dentifrice containing nHAP and a high cleaning silica system produces a greater level of stain reduction as indicated by the Modified Lobene Stain Index (MLSI) for the overall tooth surfaces than brushing with a commercial fluoride toothpaste for a period of 2 weeks.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Sep 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2025
CompletedFirst Submitted
Initial submission to the registry
September 24, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2025
CompletedFirst Posted
Study publicly available on registry
October 9, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2025
CompletedOctober 9, 2025
September 1, 2025
1 month
September 24, 2025
October 2, 2025
Conditions
Outcome Measures
Primary Outcomes (2)
WHITENING
To determine whether brushing with a whitening dentifrice containing a high cleaning silica system produces a greater level of stain reduction as indicated by the Modified Lobene Stain Index (MLSI) Area x Intensity score for the overall tooth surfaces than brushing with a commercial fluoride non-whitening dentifrice as a negative control for 2 weeks.
2 WEEKS
TOOTH COLOR
TOOTH WHITENING AND ORAL OIFT TISSUE INTEGRITY To determine the oral soft tissue (OST) tolerance of the dentifrices. To compare the change from baseline in stain levels as represented by the MLSI scores for overall, gingival, interproximal and body areas of the facial and lingual surfaces for each dentifrice after 2 weeks of product use.
2 WEEKS
Study Arms (2)
Toothpaste
EXPERIMENTALToothpaste with stain removing abilities. Toothpaste contains an abrasive system that provides increased stain removal capabilities. Product will be used by teh subject at home with a toothbrush. Instructions provided for daily use of the paste with the brush. Example brushing for two minutes per occasion.
Paste Dentifrice
PLACEBO COMPARATORToothpaste with No stain removing abilities. The abrasive system used in teh placebo, though having cleaning properties, will not have teh ability to remove excessive stain.
Interventions
Eligibility Criteria
You may qualify if:
- Consent Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.
- \) Age Aged at least 18 years.
- \) Compliance Understands and is willing, able and likely to comply with all study procedures and restrictions.
- \) General Health Good general health with no clinically significant and relevant abnormalities of medical history or dental examination in the opinion of the investigator or dental assessor.
- \) Dental Details
- Good oral health with 16 natural teeth including 11 of the 12 anterior teeth.
- All facial surfaces gradable with no large restorations as judged by the investigator or dental assessor.
You may not qualify if:
- Pregnancy Women who are known to be pregnant or who are intending to become pregnant over the duration of the study.
- \) Breast-feeding Women who are breast-feeding.
- \) Allergy/Intolerance Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
- \) Clinical Study/Experimental Medication
- Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit.
- Previous participation in this study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Boka LLClead
Study Sites (1)
Global Health Research Group
New Delhi, National Capital Territory of Delhi, 110048, India
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
ASHISH KAKAR, BDS
GHRG
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 24, 2025
First Posted
October 9, 2025
Study Start
September 1, 2025
Primary Completion
October 1, 2025
Study Completion
November 1, 2025
Last Updated
October 9, 2025
Record last verified: 2025-09